ADMA Biologics, Inc.ADMANASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P33
Within normal range
vs 3Y Ago
-3.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.95% |
| Q3 2025 | 48.21% |
| Q2 2025 | 24.82% |
| Q1 2025 | 111.25% |
| Q4 2024 | -5.10% |
| Q3 2024 | -26.43% |
| Q2 2024 | 24.44% |
| Q1 2024 | 1.01% |
| Q4 2023 | -25.25% |
| Q3 2023 | -57.52% |
| Q2 2023 | 64.09% |
| Q1 2023 | -20.41% |
| Q4 2022 | 3.11% |
| Q3 2022 | 19.30% |
| Q2 2022 | 39.94% |
| Q1 2022 | -14.39% |
| Q4 2021 | -5.39% |
| Q3 2021 | -33.51% |
| Q2 2021 | 17.34% |
| Q1 2021 | -2.55% |
| Q4 2020 | -40.68% |
| Q3 2020 | 3.14% |
| Q2 2020 | 8.35% |
| Q1 2020 | 228.89% |
| Q4 2019 | -5.41% |
| Q3 2019 | -4.95% |
| Q2 2019 | -40.62% |
| Q1 2019 | 700.77% |
| Q4 2018 | -111.00% |
| Q3 2018 | -10.52% |
| Q2 2018 | 14.85% |
| Q1 2018 | -31.25% |
| Q4 2017 | 2.77% |
| Q3 2017 | 33.54% |
| Q2 2017 | 13.89% |
| Q1 2017 | 104.45% |
| Q4 2016 | -65.22% |
| Q3 2016 | -50.67% |
| Q2 2016 | 67.67% |
| Q1 2016 | 1.55% |